PT-141 for women: when desire is what changed
In this article
PT-141, or bremelanotide, improved desire and reduced related distress in trials involving premenopausal women with acquired, generalized hypoactive sexual desire disorder. Those studies support Vyleesi, the FDA-approved branded injection. They give women researching low desire a treatment to discuss, with evidence that applies to a defined condition. RECONNECT primary publication.
If you miss the feeling of wanting sex, start there. Your goals, relationships, and experience belong in the conversation.
What can PT-141 help with?
Vyleesi treats acquired, generalized hypoactive sexual desire disorder, or HSDD, before menopause. This means desire has changed across situations and causes distress. Its indication excludes low desire explained by another medical or psychiatric condition, relationship problems, or medication or drug effects. Vyleesi prescribing information.
You do not have to arrive knowing whether HSDD describes your experience. A useful starting point is simply: “My interest in sex has changed, it bothers me, and I want to understand why.” Your own goals should lead that conversation.
How does it work?
Bremelanotide activates melanocortin receptors, including receptors found in the brain. The exact mechanism by which it improves HSDD remains unknown. Prescribing information, section 12.1.
What did the studies actually find?
The two RECONNECT trials compared bremelanotide with placebo over 24 weeks. Desire and related distress scores improved more with treatment. The trials did not find a statistically significant increase over placebo in the number of satisfying sexual events. RECONNECT primary publication.
The benefit to discuss is a possible change in desire and how its absence affects you. If interest is present but climax is difficult, our guide to PT-141 and orgasm addresses that separate question.
What if I am lesbian or bisexual?
Your relationship deserves to be part of the conversation without being treated as the explanation for your symptoms. You can ask about low desire whether your partner is a woman, a man, or nonbinary, or whether you are currently partnered at all.
RECONNECT permitted women in stable, monogamous relationships with a male or female partner. Its main publication did not report a treatment-effect estimate specifically for lesbian or bisexual participants. Same-sex partner eligibility does not establish an orientation-specific success rate. RECONNECT methods and results.
Useful questions include:
- Has my desire changed generally, or only in particular situations?
- Am I bothered by the change myself, or mostly by expectations around me?
- Is the issue wanting sex, feeling aroused, comfort during sex, orgasm, or a combination?
- What would a meaningful improvement look like in my own sex life?
There is no need to fit a heterosexual script to explain your experience. If the concern centers on different levels of interest between partners, read our guide to different sex drives in a relationship.
Questions involving gender-affirming hormones have their own evidence guide. These trials should not automatically be treated as evidence for transgender women or for hormone-associated changes in desire.
What should an assessment cover?
A sexual-health assessment should look beyond a product name. Professional guidance recommends reviewing biological, psychological, and relationship factors, addressing modifiable contributors, and matching care to the individual. Treatment can include education, sex therapy, medication, or other approaches depending on the findings. ISSWSH process-of-care guideline.
Bring a description of what changed, when it started, and any health or medication changes around that time. Mention pain, discomfort, and what you have already tried. If the timing points to an antidepressant, our antidepressants and sexual desire guide explains how to discuss options with its prescriber.
What about menopause?
Vyleesi is not approved after menopause or for sexual-performance enhancement. Current prescribing information.
Our sexual health after menopause guide covers desire, dryness, pain, treatment options, and the earlier PT-141 research in postmenopausal women.
Side effects and safety
Bremelanotide can raise blood pressure and lower heart rate; Vyleesi is contraindicated with uncontrolled hypertension or known cardiovascular disease. Nausea affected 40% of treated trial participants. Other effects include flushing, headache, injection-site reactions, vomiting, and potentially persistent skin darkening. It can affect oral-drug absorption, including oral naltrexone. Discuss pregnancy and breastfeeding before treatment. Prescribing information. Our PT-141 safety guide covers these considerations in more detail.
Is AnthologyRX’s PT-141 the same as Vyleesi?
AnthologyRX’s compounded PT-141 contains bremelanotide, the active ingredient in Vyleesi. A licensed pharmacy prepares it for an individual prescription. AnthologyRX treatment details.
The finished preparation can differ in concentration, other ingredients, and delivery system. It is not FDA-approved or established as equivalent to Vyleesi in safety, effectiveness, or quality. FDA compounding information.
Make the next conversation a useful one
You deserve clear answers about the medication being considered, the evidence behind it, and what happens if it does not suit you. Review the preparation, included care, and current plan details before starting an assessment.
